Where does Genmab A/S rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Genmab A/S ranks #4,193 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Genmab A/S hold?

Genmab A/S holds 85 US utility patents granted between 2015 and 2025, spanning 8 technology areas.

What is Genmab A/S's Innovation Score?

Genmab A/S has an Innovation Score of 46.5 out of 100 (top 20% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Genmab A/S focus on?

Genmab A/S's top technology area is C07K (Peptides) with 85 patents. Grants appear in 8 CPC subclasses total.

Is Genmab A/S's patent grant rate increasing or decreasing?

Genmab A/S's recent grant velocity is +17% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Genmab A/S's patents?

Genmab A/S's patents average 27.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Genmab A/S patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Genmab A/S

USPTO PatentsView assignee record - 85 granted patents across 8 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Genmab ranks #4,193 of 49,997 tracked US assignees by granted-patent volume, with 85 patents across 8 technology areas.

#4,193
of 49,997 US assignees by volume: Top 20%
by Innovation Score (46.5/100): 27.1
avg claims per patent: +17%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4193 · Foreign Corporation #4,193 · 85 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · VEL-UP · BOOK-FULL

GRANTS-SMALL 85 grants
TOP-DECILE #4,193/49,997
PHOTO-FINISH Cooper-Standard…
CPC-NARROW C07K · 8 areas
INNOV-PAR 46.5/100
CLAIMS-DENSE 27.1 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-UP +17% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Cooper-Standard Automotive Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Ambarella · near

47
Blueair AB · near

47
Genmab A/S · this assignee

47
Nasdaq Technology AB · near

47
Toshiba Lighting &… · near

47
3D Lighting… · lowest

7

What this shows Genmab's Innovation Score is 46.5/100 (top 20% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Genmab's grants concentrate

Genmab A/S is a focused PatentsView assignee: 8 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2015 (10 grants) versus a trough of 4 in 2018. By volume, Genmab sits between Cooper-Standard Automotive Inc. and HER Majesty THE Queen IN Right OF Canada AS Represented BY THE Minister OF Natual Resources.

Genmab's three-year grant acceleration

From 2019–2021 to 2022–2024, Genmab A/S moved from 26 to 24 grants (0.92x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Cooper-standard A…

85
Cormatrix Cardiov…

85
Digitalglobe

85
Flint Hills Scien…

85
Given Imaging

85
Hardware Resources

85
Hasco Vision Tech…

85
HER Majesty THE Q…

85
Genmab A/S ◀

85

What this shows Genmab holds 85 patents at rank #4,193, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Genmab

By rank, the assignees closest to #4,193 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Genmab's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Genmab, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (47 here).

Nasdaq Technology AB 47 Ambarella, Inc. 47 Toshiba Lighting & Technology Corporation 47 Blueair AB 47

Similar claim depth

Nearest assignees by average claims per patent (27.1 here).

Ecosense Lighting Inc. 27.2 avg Affectiva, Inc. 27.2 avg Comcast Cable Communications, LLC 27.0 avg Sunrise Memory Corporation 27.4 avg

Genmab's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

47 Top 20% higher than 80% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Genmab A/S patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	10	11.8%
2016	6	7.1%
2017	8	9.4%
2018	4	4.7%
2019	8	9.4%
2020	9	10.6%
2021	9	10.6%
2022	9	10.6%
2023	8	9.4%
2024	7	8.2%
2025partial year	7	8.2%

Which technologies does Genmab A/S patent most?

C07K - Peptides 85

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 77

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 70

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 26

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 6

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 3

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 3

C12Y - Enzymes 1

Top 8 of 8 technology areas

Where it ranks

Overall rank by patents

#4,193

of 49,997 tracked assignees

Innovation Score

46.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Genmab A/S's patent record in context - here's where to go next.

Genmab A/S's lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #4,193 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Genmab A/S against Cooper-Standard Automotive Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 46.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.